EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China

Mengmeng Liu, Tong Liu

Frontiers in Pharmacology · 10.08.2026 · 17

DOI: 10.3389/fphar.2026.1746058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.08.2026. Verfasst von Mengmeng Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluates the cost-effectiveness of triplet therapy of encorafenib, binimetinib, and cetuximab in contrast to doublet therapy of encorafenib and cetuximab or a control group of cetuximab plus FOLFIRI as second-line or subsequent treatment for advanced or metastatic colorectal cancer (mCRC) patients with BRAF V600 E mutation-positive status in China.

Methods

An economic evaluation using a 3-state partitioned survival model assessed the cost-effectiveness of triplet therapy versus doublet therapy, triplet therapy versus the control group, or doublet therapy versus the control group.

Results

The anticipated costs for triplet therapy, doublet therapy and control therapy were 58,614.81 USD, 46,521.37 USD and 15,710.17 USD, respectively. The estimated utilities of triplet therapy, doublet therapy and control therapy were 0.84 QALYs, 0.76 QALYs and 0.53 QALYs. The ICER of triplet-therapy vs. doublet-therapy or triplet-therapy vs. control therapy or doublet-therapy vs. control therapy was 154,675.20 USD/QALY, 140,355.45 USD/QALY, or 135,434.11 USD/QALY.

Conclusion

Our results suggested that triplet therapy was not cost-effective compared to doublet therapy and control therapy as second-line or subsequent treatment for advanced or mCRC patients with BRAF V600 E mutation at a WTP threshold of 40,000 USD/QALY.

Schlagwörter

Stichwörter der Autor:innen

binimetinibcetuximabcolorectal cancercost-effectivenessencorafenibpharmacoeconomics

Autor:innen und Institutionen

  • Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

Zitieren

APA

Liu, M., & Liu, T. (2026). Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1746058

Vancouver

Liu M, Liu T. Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1746058

BibTeX
@article{Liu2026,
  author = {Liu, Mengmeng and Liu, Tong},
  title = {Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1746058}
}
Kostenlos starten →